Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Park Medi World IPO Review & Investor Guide

By Jagat Joshi
December 10, 2025

Park Medi World IPO opens on December 10, 2025, and closes on December 12, 2025. The Park Medi World IPO price band is set between ₹154 to ₹162 per share, with a face value of ₹2 each. As per the RHP, the company plans to raise around ₹920 crores through an IPO.

For investors, deciding whether the Park Medi World IPO is a good investment can be quite challenging. If you are unsure and still thinking about whether to apply or skip this IPO, don’t worry. In this article, we present the top key factors and a detailed review of the Park Medi World IPO. This will help you analyze the strengths, risks, and financial details of the Park Medi World IPO, making your investment decision better.

About Company

Park Modi is the second-largest Indian private hospital chain in India. Moreover, they have around 3,000 beds as of September 30, 2024. Moreover, they have eight hospitals in Haryana, one in New Delhi, two in Punjab, and two in Rajasthan.

The company offers more than 30 specialty and super-specialty services, which include internal medicine, neurology, urology, gastroenterology, general surgery, orthopedics, and oncology.

Moreover, as of September 30, 2024, they have a workforce of 891 doctors, 1,912 nurses, 671 medical professionals, and 1,761 support staff. Also, they have experienced and skilled team members who are one of the reasons for the company’s growth.

Strengths

Under the brand Park, the company runs 14 NABH-accredited multi-super specialty hospitals with over 30 super specialty and specialty services.

They are the 2nd largest private hospital chain in North India with a bed capacity of 3,000 beds.

In FY25, the profit jumped by 40% and revenue increased by 13%.

Over the last 3 years, the company has had positive cash flow.

The company consists of 1000+ qualified doctors and a professional management team with 25 years of experience in the nursing home and hospital business.

Weaknesses

The company mainly runs its business on doctors, nurses, medical staff, and support teams. The attrition rate of the company is 33.72%. If unable to keep or hire these professionals could impact the business, and the finances may suffer.

Park Medi generates more than 70% of revenue from Haryana Facilities only.

The company is heavily dependent on the inpatient department. If this area underperforms, it could negatively impact the company’s finances.

We saw a drop in the bed occupancy rate by 75% to 61% which can be concerning for healthcare firms and may impact the hospital’s revenue growth.

Park Medi World IPO Review

Reviewer	Recommendation
IPO Watch	May Apply
Axis Capital	Not Rated
JM Financial Services Limited (JMFS)	Not Rated
Swastika Investmart Ltd	Apply

Park Medi World IPO Details

IPO Open Date:	December 10, 2025
IPO Close Date:	December 12, 2025
Face Value:	₹2 Per Equity Share
IPO Price Band:	₹154 to ₹162 Per Share
Issue Size:	₹920 Crores
Fresh Issue	₹770 Crores
Offer-for-Sale	Up to 92,59,259 equity shares
Registrar	Kfin Technologies Ltd.
IPO Lead Managers	Nuvama Wealth Management Limited CLSA India Private Limited DAM Capital Advisors Limited Intensive Fiscal Services Private Limited
Basis of Allotment	December 15, 2025
IPO Listing Date:	December 17, 2025
Listing	BSE, NSE

Financial Performance Trend Details

Particulars	30 Sep 2025	31 Mar 2025	31 Mar 2024
Total Income	₹823.39 crores	₹1,425.97 crores	₹1,263.08 crores
EBITDA	₹217.14 crores	₹372.17 crores	₹310.30 crores
EBITDA Margin	26.85%	26.71%	25.21%
Profit after Tax (PAT)	₹139.14 crores	₹213.22 crores	₹152.01 crores
PAT Margin	17.21%	15.30%	12.35%
Net Worth	₹1,153.05 Crores	₹1,021.86 Crores	₹815.98 Crores
Reserve and Surplus	₹1,187.77 Crores	₹1,049.40 Crores	₹858.63 Crores
Total Borrowings	₹733.91 Crores	₹682.07 Crores	₹686.71 Crores

Peer Comparison with the Company

Name of the Company	Face Value (₹)	Basic EPS (₹)	Diluted EPS(₹)	RONW (%)	P/E Ratio	NAV(₹)
Park Medi World	2	5.55	5.55	20.08%	[●]	26.58
Listed Peers
Apollo Hospitals Enterprise Limited	5	100.56	100.56	17.63%	73.43	570.37
Fortis Healthcare Limited	10	10.26	10.26	8.69%	90.42	118.06
Narayana Hrudalaya Limited	10	38.90	38.90	21.80%	50.10	177.37
Max Healthcare Institute Limited	10	11.07	11.01	11.47%	101.54	96.50
Krishna Institute of Medical Sciences Limited	2	9.61	9.61	17.89%	69.53	53.43
Global Health Limited	2	17.92	17.92	14.27%	66.41	125.64
Jupiter Lifeline Hospitals Ltd	10	29.47	29.47	14.27%	48.59	206.85
Yatharth Hospital & Trauma Care Services Limited	10	14.72	14.72	8.15%	52.85	166.62

Key Performance Indicator

KPI	Values
ROE	20.68%
ROCE	17.47%
RoNW	20.08%
EBITDA Margin	26.71%
Price to Book Value	16.09
PAT Margin	15.30%
Debt/Equity	0.61

Promoters & Track Records, if any

Dr. Ajit Gupta, born on October 12, 1957, aged 68 years, is one of our Promoters and is the Chairman and Whole-Time Director of our Company. He holds 331,433,596 of Equity Shares, representing 86.22% of pre-Offer Equity share capital in the company.

Dr. Ankit Gupta, born on January 21, 1982, aged 43 years, is one of our Promoters and is the Managing Director of our Company. He holds 35,874,165 of Equity Shares, representing 9.33% of pre-Offer Equity share capital in the company.

Industry Peer Group P/E ratio

In the healthcare & Hospitals industry, the P/E ratio for Park Medi World ranges from a low of 48.59 to a high of 101.54, with the industry composite at 69.11.

Expansion

The proceeds raised from the fresh issue will be used towards the development of a new hospital and the expansion of the existing hospital by our certain Subsidiaries, Park Medicity (NCR) and Blue Heavens.

A portion of the funds will be utilized towards repayment/prepayment of certain borrowings taken by the company and certain of the Subsidiaries.

Some funds will be used for the purchase of medical equipment by the Company and certain Subsidiaries, Blue Heavens, and Ratangiri.

Lastly, the remaining funds will be used for the general corporate purposes.

Park Medi World IPO – Should You Apply or Not?

Park Medi World IPO features diversified healthcare services, steady revenue growth, appealing valuation, growing financial performance, and sector tailwinds that promote future growth. On the other hand, dependence on inpatient services, high attrition rate, Limited geographic presence, and competitive industry pressures remain key concerns.

As of December 9th, the GMP of Park Medi World is ₹29, indicating a listing gain of around 16% to 18%. Short-term investors may apply for the IPO for listing gains after evaluating Grey Market Premium (GMP) trends and strong brand recall. Whereas Long-term investors must analyze the risks, limited geographic concentration, and drop in bed occupancy rate before investing their money in it.

Please note:

Investors are advised to make their own decisions and apply entirely at their own risk. This article is written using information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.